BANK VONTOBEL/PUT/BIONTECH ADR/115/0.1/21.06.24 Share Price

Warrant

PQ39V

DE000VM7WG70

Real-time Euronext Paris 16:34:55 16/05/2024 BST
1.975 EUR -2.95% Intraday chart for BANK VONTOBEL/PUT/BIONTECH ADR/115/0.1/21.06.24
Current month-13.95%
1 month-19.09%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
16/05/24 1.975 -2.95%
15/05/24 2.035 -2.40%
14/05/24 2.085 +1.46%
13/05/24 2.055 +1.48%
10/05/24 2.025 -0.98%

Real-time Euronext Paris

Last update May 16, 2024 at 04:34 pm

More quotes

Static data

Product typeWarrants
Buy / SellPUT
Underlying BIONTECH SE
IssuerLogo Issuer Vontobel Vontobel
PQ39V
ISINDE000VM7WG70
Date issued 04/01/2024
Strike 115 $
Maturity 21/06/2024 (36 Days)
Parity 10 : 1
Emission price 1.15
Emission volume N/A
Settlement Por diferencias
Currency EUR

Technical Indicators

Highest since issue 2.74
Lowest since issue 1.195
Delta-0.93x
Omega 3.903
Premium-0.25x
Gearing4.19x
Moneyness 1.241
Difference Strike 21.83 $
Difference Strike %+18.98%
Spread 0.01
Spread %0.49%
Theoretical value 2.015
Implied Volatility 35.62 %
Total Loss Probability 2.601 %
Intrinsic value 2.058
Present value -0.042977
Break even 93.10 €
Theta0x
Vega0x
Rho-0.01x

Company Profile

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Sector
-
More about the company

Ratings for BioNTech SE

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: BioNTech SE

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
84.83 EUR
Average target price
105.4 EUR
Spread / Average Target
+24.23%
Consensus
  1. Stock Market
  2. Warrants
  3. PQ39V Warrant